By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Swedish Orphan Biovitrum 


  76  Stockholm  Sweden
Phone: 46-8-697-20-00 Fax: n/a



Company News
Sobi Release: FDA Approves ORFADIN (Nitisinone) Oral Suspension 4/27/2016 6:09:52 AM
Sobi Partners With U.S. And Canadian Advocates, Legislators To Raise Awareness On Rare Disease Day 2/29/2016 9:56:27 AM
Invitation - Presentation Of Sobi's Third Quarter Results 2015 10/20/2015 12:27:23 PM
Biogen (BIIB) and Sobi Release: Haemophilia Therapy From Largest Multi-Year Donation Now Available To Patients In Developing World 10/12/2015 9:42:53 AM
Sobi CEO Invests In 2015 LTI Programme And Divests A Portion Of Incentive Shares 9/29/2015 9:19:27 AM
Biogen (BIIB) And Sobi Receive Positive Opinion From CHMP For ELOCTA (Rfviiifc) For The Treatment Of Hemophilia A 9/25/2015 10:41:57 AM
Sobi Opens European And Benelux Office In Brussels 9/8/2015 10:42:22 AM
Sobi Celebrates 25 Years With Orfadin (Nitisinone) - A Result Of Ground-Breaking Swedish Research 9/4/2015 9:03:13 AM
Biogen (BIIB) And Sobi Announce European Medicines Agency Validates ALPROLIX (rFIXFc) Marketing Authorization Application 6/26/2015 12:00:27 PM
Invitation - Presentation Of Sobi's Second Quarter 2015 6/26/2015 9:33:07 AM